Spectral karyotyping analysis of lymphomas and MPDs arising in Egr1-deficient mice following ENU treatment
| Case no. . | Mouse . | Genotype . | Tissue . | Tumor . | Karyotype* . |
|---|---|---|---|---|---|
| 32444 | 240 | Egr1+/− | Spleen | Lymphoma | 40,XX[12] |
| 32365 | 256 | Egr1+/− | Spleen | Lymphoma | 40,XX[10] |
| 32488 | 195 | Egr1+/− | Spleen | Lymphoma | 41,XY,+mar[2]/ 40,XY[9] |
| 32516 | 101 | Egr1+/− | Lung | Lymphoma | 40,XY[8]/ 40,XY,t(2;4)(B;B1)[1]/ 80,XXYY[1] |
| 32606 | 246 | Egr1+/− | Spleen | Lymphoma | 40,XY[8]/ 39,XY,del(12)(C2F2 or A2D1),-19[1]/ 80,XXYY[1]/ 78,XXYY,-1,-4,-7,+9,+10,+11,+15,-16,-17,-17[1] 82,XXYY,+8,+12,del(12)(C2F2 or A2D1),+15,-19[1] |
| 32557 | 313 | Egr1−/− | Lung | Lymphoma | 40,XY[10] |
| 32476 | 249 | Egr1−/− | Spleen | Lymphoma | 40,XY[10] |
| 32605 | 93 | Egr1+/− | Spleen | MPD | 40,XY[10]/ 80,XXYY[1] |
| 33325 | 243 | Egr1+/− | Spleen | MPD | 40,XY[9]/ 40,XY,-12,+18[1] |
| 33327 | 257 | Egr1+/− | Spleen | MPD | 40,XY[9]/ 80,XXYY[1] |
| 32770 | 251 | Egr1−/− | Spleen | MPD | 40,XX[10] |
| 32950 | 95 | Egr1−/− | Spleen | MPD | 41,XY,+15[2]/ 40,XY[8] |
| 33949 | 765 | Egr1−/− | Spleen | MPD | 40,XY[10] |
| Case no. . | Mouse . | Genotype . | Tissue . | Tumor . | Karyotype* . |
|---|---|---|---|---|---|
| 32444 | 240 | Egr1+/− | Spleen | Lymphoma | 40,XX[12] |
| 32365 | 256 | Egr1+/− | Spleen | Lymphoma | 40,XX[10] |
| 32488 | 195 | Egr1+/− | Spleen | Lymphoma | 41,XY,+mar[2]/ 40,XY[9] |
| 32516 | 101 | Egr1+/− | Lung | Lymphoma | 40,XY[8]/ 40,XY,t(2;4)(B;B1)[1]/ 80,XXYY[1] |
| 32606 | 246 | Egr1+/− | Spleen | Lymphoma | 40,XY[8]/ 39,XY,del(12)(C2F2 or A2D1),-19[1]/ 80,XXYY[1]/ 78,XXYY,-1,-4,-7,+9,+10,+11,+15,-16,-17,-17[1] 82,XXYY,+8,+12,del(12)(C2F2 or A2D1),+15,-19[1] |
| 32557 | 313 | Egr1−/− | Lung | Lymphoma | 40,XY[10] |
| 32476 | 249 | Egr1−/− | Spleen | Lymphoma | 40,XY[10] |
| 32605 | 93 | Egr1+/− | Spleen | MPD | 40,XY[10]/ 80,XXYY[1] |
| 33325 | 243 | Egr1+/− | Spleen | MPD | 40,XY[9]/ 40,XY,-12,+18[1] |
| 33327 | 257 | Egr1+/− | Spleen | MPD | 40,XY[9]/ 80,XXYY[1] |
| 32770 | 251 | Egr1−/− | Spleen | MPD | 40,XX[10] |
| 32950 | 95 | Egr1−/− | Spleen | MPD | 41,XY,+15[2]/ 40,XY[8] |
| 33949 | 765 | Egr1−/− | Spleen | MPD | 40,XY[10] |
A minimum of 10 metaphase cells were analyzed for each sample.